The Lea’s Foundation Center for Hematologic Disorders
The Lea’s Foundation Center for Hematologic Disorders was
dedicated in 2007 at the University of Connecticut Health
Center. This center of excellence offers world-class care for patients with benign and
malignant blood disorders including sickle cell disease,
bleeding and clotting disorders, leukemia, lymphoma, multiple
myeloma and others.
The center was made possible by a $1.25 million donation from
Foundation for Leukemia Research, Inc., a prominent
Hartford nonprofit that provides support for blood cancer
research efforts to the Neag Comprehensive Cancer Center.
Services include diagnosis and treatment of patients with
blood cancers – lymphoma, leukemia, myeloproliferative
disorders, myelodysplastic disorders, multiple myeloma, and
others – and so-called non-cancerous blood diseases, including
low blood counts – low red blood cell count or anemia, low white
blood cell count or leukopenia, and low platelet count or
thrombocytopenia – as well as sickle cell diseases, disorders of
bleeding or thrombosis.
- Hemophilia/Thrombophilia Treatment Center
This federally funded program offers multidisciplinary
care to individuals with hemophilia, von Willebrand's
disease, other bleeding disorders and disorders of
thrombosis (abnormal blood clotting). For further
information, visit the
Hemophilia/Thrombophilia Treatment Center page.
- Sickle Cell Disease
This program offers care to patients with a range of
sickle cell disorders. Among other activities, our staff
works closely with the pediatric hematologists and others at
CCMC in order to assure a smooth transition of care from
adolescence to adult providers. Close collaboration with
community based organizations also occurs in order to help
with the delivery of care and improve quality of life for
individuals with these disorders. For further information,
visit the Comprehensive Sickle Cell Clinical and Research Center page.
- Blood Cancers and Related Disorders
Hematologists-Oncologists at our center care for
individuals with lymphoma, leukemia, multiple myeloma,
myelodysplasia, myeloproliferative disorders and other
related blood disorders.
Please see the Clinical Trials page for a list of ongoing clinical trials.
Many blood disorders are the focus of laboratory
investigation at the UConn School of Medicine. In some
instances, our physician scientists are collaborating with basic
scientists in what is known as translational research – the
application of basic science research to patient care. Some
areas of ongoing research include:
- The role of heat shock proteins in multiple myeloma
- The role of cell signaling (SH2 profiling) in
- Phospodiesterases in leukemia resistance;
- Sickle cell disease and immune function; and
- Inflammation and hemostasis.
Hematologic Disorders Information
Please follow the links below to obtain up-to-date information from the
National Cancer Institute. These links delve into cancer prevention, detection and treatment,
and provide a wealth of additional resources.
Our Specialists and Staff
Request an Appointment
For further information or to arrange
for a consultation with Hematology Services, call 800-579-7822
At the UConn Health
On the Web